{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T16:10:31Z","timestamp":1719504631135},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Fortschr Neurol Psychiatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Anliegen Clozapin zeigt in vielen Untersuchungen eine \u00fcberlegene\nWirksamkeit gegen\u00fcber anderen Antipsychotika. Zur Verschreibungspraxis\nvon Clozapin und den Charakteristika der damit behandelten Patienten gibt es\nbislang wenig systematisch erhobene Daten.<\/jats:p><jats:p>\n          Methode Retrospektive Auswertung aller 392 Behandlungsverl\u00e4ufe von\nstation\u00e4r behandelten Patienten mit schizophrenen Psychosen eines\nJahres. Detaillierte Analyse der mit Clozapin behandelten Patienten\neinschlie\u00dflich der Dosierungen und der zus\u00e4tzlichen\nMedikation.<\/jats:p><jats:p>\n          Ergebnis Patienten mit Clozapinbehandlung weisen eine h\u00f6here\nKrankheitsschwere als Patienten ohne Clozapinbehandlung auf. Sie erhalten\nh\u00e4ufiger pharmakologische Kombinationsbehandlungen, die den\ngegenw\u00e4rtigen Leitlinienempfehlungen teilweise erheblich\nentgegenstehen.<\/jats:p><jats:p>\n          Schlussfolgerung Die Ergebnisse unterstreichen die ausgepr\u00e4gte\nKrankheitsschwere von Patienten mit einer Clozapinbehandlung und belegen\nHinweise aus der Literatur auf die begrenzte Umsetzung von Leitlinien in die\nVerschreibungspraxis. Die durchgef\u00fchrte Untersuchung dient als\nPilotuntersuchung einer multizentrischen Studie zur Verschreibungspraxis von\nClozapin in psychiatrischen Kliniken unterschiedlicher Regionen.<\/jats:p>","DOI":"10.1055\/a-1526-2269","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T23:00:41Z","timestamp":1628809241000},"page":"622-629","source":"Crossref","is-referenced-by-count":0,"title":["Clozapin in der Behandlung schizophrener Psychosen\nPatientencharakteristika und antipsychotische Kombinationstherapien bei einem\nBehandlungsjahrgang eines psychiatrischen\nVersorgungskrankenhauses"],"prefix":"10.1055","volume":"89","author":[{"given":"Michael","family":"Rentrop","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Huhn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schwerth\u00f6ffer","sequence":"first","affiliation":[{"name":"Psychiatrie, Klinik f\u00fcr Psychiatrie und Psychotherapie der\nTU-M\u00fcnchen, M\u00fcnchen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"ref3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/s0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute\ntreatment of adults with multi-episode schizophrenia: a systematic review and\nnetwork meta-analysis","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet (London, England)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fpsyt.2018.00231","article-title":"Prescription and Underprescription of Clozapine in Dutch Ambulatory Care","volume":"9","author":"Y C van der Zalm","year":"2018","journal-title":"Frontiers in psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-2002-31523","article-title":"Psychopharmacological treatment of aggression in schizophrenic patients","volume":"35","author":"T Brieden","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/s2215-0366(16)30030-x","article-title":"Suicide prevention strategies revisited: 10-year systematic review","volume":"3","author":"G Zalsman","year":"2016","journal-title":"The lancet Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1176\/ps.41.8.886","article-title":"The European experience with use of clozapine","volume":"41","author":"D Naber","year":"1990","journal-title":"Hospital & community psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique Effects of Clozapine: A Pharmacological Perspective","volume":"82","author":"J Y Khokhar","year":"2018","journal-title":"Advances in pharmacology (San Diego, Calif)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1055\/s-0033-1343185","article-title":"Antipsychotische Polypharmazie bei Patienten mit Schizophrenie und hoher\nVersorgungsinanspruchnahme","volume":"40","author":"C Schmidt-Kraepelin","year":"2013","journal-title":"Psychiatrische Praxis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and\nmeta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"J A Gallego","year":"2012","journal-title":"Schizophrenia research"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2017.0624","article-title":"Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic\nMonotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the\nMeta-analytic Evidence","volume":"74","author":"C U Correll","year":"2017","journal-title":"JAMA psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"g1173","DOI":"10.1136\/bmj.g1173","article-title":"Management of psychosis and schizophrenia in adults: summary of updated NICE\nguidance","volume":"348","author":"E Kuipers","year":"2014","journal-title":"BMJ (Clinical research ed)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge\nand behavior","volume":"131","author":"C U Correll","year":"2011","journal-title":"Schizophrenia research"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4088\/JCP.19ac13118","article-title":"Antipsychotic Polypharmacy in Schizophrenia: Why Not?","author":"D Guinart","year":"2020","journal-title":"The Journal of clinical psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/wps.20387","article-title":"Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review,\nmeta-analysis and meta-regression analysis","volume":"16","author":"B Galling","year":"2017","journal-title":"World psychiatry: official journal of the World Psychiatric\nAssociation (WPA)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1093\/schbul\/sbx024.010","article-title":"SU11. Amisulpride Augmentation of Clozapine for Treatment-Refractory\nSchizophrenia: The AMICUS Study","volume":"43","author":"T Barnes","year":"2017","journal-title":"Schizophrenia bulletin"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1017\/s1461145710000490","article-title":"Effects of adjunctive treatment with aripiprazole on body weight and clinical\nefficacy in schizophrenia patients treated with clozapine: a randomized,\ndouble-blind, placebo-controlled trial","volume":"13","author":"W W Fleischhacker","year":"2010","journal-title":"The international journal of neuropsychopharmacology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric\nRehospitalization Among Adults With Schizophrenia","volume":"76","author":"J Tiihonen","year":"2019","journal-title":"JAMA psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"112671","DOI":"10.1016\/j.psychres.2019.112671","article-title":"The effect of Clinical Practice Guidelines on prescribing practice in mental\nhealth: A systematic review","volume":"284","author":"T Nguyen","year":"2020","journal-title":"Psychiatry research"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00213-012-2773-2","article-title":"Outcome definitions and clinical predictors influence pharmacogenetic\nassociations between HTR3A gene polymorphisms and response to clozapine in\npatients with schizophrenia","volume":"224","author":"A P Rajkumar","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/acps.12954","article-title":"Clozapine as a first- or second-line treatment in schizophrenia: a systematic\nreview and meta-analysis","volume":"138","author":"C Okhuijsen-Pfeifer","year":"2018","journal-title":"Acta psychiatrica Scandinavica"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/yic.0000000000000336","article-title":"The effects of adding long-acting injectable antipsychotic drugs to clozapine on\nrelapse and hospitalization in patients with treatment-resistant schizophrenia:\na mirror-image retrospective study","volume":"36","author":"A M Caliskan","year":"2021","journal-title":"International clinical psychopharmacology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003088-199324020-00005","article-title":"Pharmacokinetics and pharmacodynamics of clozapine","volume":"24","author":"M W Jann","year":"1993","journal-title":"Clinical pharmacokinetics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1080\/17425255.2020.1821646","article-title":"Antipsychotic polypharmacy in schizophrenia: evolving evidence and\nrationale","volume":"16","author":"J M Azorin","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Fortschritte der Neurologie \u00b7 Psychiatrie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1526-2269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T15:38:22Z","timestamp":1719502702000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1526-2269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,6]]},"published-print":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1526-2269","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-4299","1439-3522"],"issn-type":[{"value":"0720-4299","type":"print"},{"value":"1439-3522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]}}}